Eli Lilly and Company (LLY)vsTransMedics Group Inc (TMDX)
LLY
Eli Lilly and Company
$1,430.13
-0.70%
HEALTHCARE · Cap: $1.26T
TMDX
TransMedics Group Inc
$92.00
-0.01%
HEALTHCARE · Cap: $3.16B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 11782% more annual revenue ($86.46B vs $727.65M). LLY leads profitability with a 31.9% profit margin vs 19.9%. TMDX appears more attractively valued with a PEG of 0.80. LLY earns a higher WallStSmart Score of 74/100 (B).
LLY
Strong Buy74
out of 100
Grade: B
TMDX
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+56.3%
Fair Value
$304.76
Current Price
$92.00
$212.76 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 68 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 53.7%
Revenue surging 38.6% year-over-year
Generating 8.2B in free cash flow
Every $100 of equity generates 35 in profit
Revenue surging 41.1% year-over-year
Growing faster than its price suggests
Areas to Watch
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 31.6x book value
Distress zone — elevated risk
Elevated debt levels
Earnings declined 29.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.9% and operating margin at 53.7%. Revenue growth of 38.6% demonstrates continued momentum.
Bull Case : TMDX
The strongest argument for TMDX centers on Return on Equity, Revenue Growth, PEG Ratio. Profitability is solid with margins at 19.9% and operating margin at 13.9%. Revenue growth of 41.1% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 46.0x leaves little room for execution misses.
Bear Case : TMDX
The primary concerns for TMDX are Altman Z-Score, Debt/Equity, EPS Growth. Debt-to-equity of 1.67 is elevated, increasing financial risk.
Key Dynamics to Monitor
TMDX carries more volatility with a beta of 2.10 — expect wider price swings.
TMDX is growing revenue faster at 41.1% — sustainability is the question.
LLY generates stronger free cash flow (8.2B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (74/100 vs 62/100), backed by strong 31.9% margins and 38.6% revenue growth. TMDX offers better value entry with a 56.3% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →TransMedics Group Inc
HEALTHCARE · MEDICAL DEVICES · USA
TransMedics Group, Inc., a commercial-stage medical technology company, is dedicated to transforming organ transplant therapy for patients with end-stage organ failure in the United States and internationally. The company is headquartered in Andover, Massachusetts.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?